Latest news with #DOCS
Yahoo
7 hours ago
- Business
- Yahoo
Doximity (DOCS) Soars 14% on Strong Earnings, Merger with AI-Powered Platform
We recently published . Doximity Inc. (NYSE:DOCS) is one of the best-performing stocks on Friday. Doximity Inc. extended its winning streak to a third consecutive day on Friday, jumping 13.71 percent to close at $66.58 apiece as investors continued to load up positions following a strong earnings performance and its increasing adoption of artificial intelligence. In its updated report, Doximity, Inc. (NYSE:DOCS) registered a net income of $53.3 million in the first quarter of fiscal year 2026, marking a 28-percent growth from the $41.37 million in the same period last year. Revenues grew by 15 percent to $145.9 million from $126.68 million year-on-year. ESB Professional/ For the full fiscal year 2026 period, Doximity, Inc. (NYSE:DOCS) targets to book $628 million to $636 million in revenues, or a 10 to 11.5 percent growth from the $570.4 million registered in full fiscal year 2025. Adjusted EBITDA is also expected to grow between 8.7 and 11.2 percent to $341 million to $349 million, from the $313.8 million posted a year earlier. Earlier this week, Doximity, Inc. (NYSE:DOCS) announced the completion of its $63 million merger with AI-powered platform Pathway Medical Inc. According to Doximity, Inc. (NYSE:DOCS), Pathway's model outperforms others in clinical accuracy, recently scoring a record 96 percent on the US Medical Licensing Examination benchmark. 'There's a growing need for clinical tools that combine trusted evidence with the speed and adaptability of AI,' said Pathway CEO Jon Hershon. 'Hundreds of thousands of users have registered for Pathway, and thousands pay $300 per year for our premium product. With Doximity, one of the most trusted platforms in healthcare, we're now bringing that experience to millions for free, built directly into the tools they already use at the point of care.' While we acknowledge the potential of DOCS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Sign in to access your portfolio
Yahoo
9 hours ago
- Business
- Yahoo
Why Is Doximity (DOCS) Stock Rocketing Higher Today
What Happened? Shares of healthcare professional network Doximity (NYSE:DOCS) jumped 11.6% in the afternoon session after the company reported strong second-quarter 2025 results that surpassed Wall Street's expectations and raised its full-year guidance. The digital platform for U.S. medical professionals reported revenue of $145.9 million, an increase of 15.2% year over year, and adjusted earnings per share (EPS) of $0.36. These results comfortably beat analyst estimates, which called for $139.6 million in revenue and an adjusted EPS of $0.31. Furthermore, Doximity provided strong guidance for the next quarter, with its revenue forecast of $157.5 million coming in 5% above expectations. The company also raised its full-year revenue guidance to a midpoint of $632 million. The strong performance and optimistic outlook signaled healthy demand and operational efficiency, boosting investor confidence. Is now the time to buy Doximity? Access our full analysis report here, it's free. What Is The Market Telling Us Doximity's shares are very volatile and have had 25 moves greater than 5% over the last year. But moves this big are rare even for Doximity and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 7 days ago when the stock dropped 4.2% on the news that the White House announced a new round of steep global tariffs, sparking concerns of a trade war and its impact on the U.S. and global economies. This move creates significant uncertainty for businesses and investors. The new tariffs, with rates of up to 41% on imports from 68 countries and the European Union, prompted a broad market sell-off, with the tech-heavy Nasdaq index showing notable weakness. Adding to the bearish sentiment was a weaker-than-expected July jobs report, which revealed that employers created only 73,000 jobs, far below economists' expectations. This combination of trade fears and signs of a slowing labor market has created a "risk-off" environment, leading investors to pull back from growth-oriented sectors like software and technology. Doximity is up 21.5% since the beginning of the year, but at $65.08 per share, it is still trading 21.7% below its 52-week high of $83.14 from February 2025. Investors who bought $1,000 worth of Doximity's shares at the IPO in June 2021 would now be looking at an investment worth $1,228. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
Yahoo
15-07-2025
- Business
- Yahoo
Doximity (DOCS) Rises Higher Than Market: Key Facts
In the latest trading session, Doximity (DOCS) closed at $61.55, marking a +2.24% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.14%. On the other hand, the Dow registered a gain of 0.2%, and the technology-centric Nasdaq increased by 0.27%. Prior to today's trading, shares of the medical social networking site had gained 7.65% outpaced the Medical sector's loss of 1.34% and the S&P 500's gain of 3.97%. The investment community will be closely monitoring the performance of Doximity in its forthcoming earnings report. It is anticipated that the company will report an EPS of $0.31, marking a 10.71% rise compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $139.67 million, indicating a 10.26% upward movement from the same quarter last year. For the annual period, the Zacks Consensus Estimates anticipate earnings of $1.46 per share and a revenue of $625.72 million, signifying shifts of +2.82% and +9.7%, respectively, from the last year. It's also important for investors to be aware of any recent modifications to analyst estimates for Doximity. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.55% downward. Doximity presently features a Zacks Rank of #3 (Hold). With respect to valuation, Doximity is currently being traded at a Forward P/E ratio of 41.26. For comparison, its industry has an average Forward P/E of 28.13, which means Doximity is trading at a premium to the group. It's also important to note that DOCS currently trades at a PEG ratio of 4.48. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As of the close of trade yesterday, the Medical Info Systems industry held an average PEG ratio of 2.64. The Medical Info Systems industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 85, finds itself in the top 35% echelons of all 250+ industries. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Doximity, Inc. (DOCS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
11-06-2025
- Business
- Yahoo
DOCS Boosts Client Retention via Workflow Integration and AI Tools
The renowned digital platform for U.S. medical professionals, Doximity, Inc.'s DOCS client engagement and retention strategy is built around deeply integrated, physician-first tools across its Marketing, Hiring and Workflow Solutions. By focusing on clinical utility and streamlining healthcare professionals' day-to-day workflows, the platform has seen high adoption — more than 620,000 unique providers used its clinical tools in the fourth quarter of fiscal 2025. This functional alignment with medical practices enhances relevance and trust, making Doximity an essential platform for providers. DOCS' Marketing Solutions deliver personalized campaigns through newsfeeds, workflow placements and peer messaging modules. Leveraging AI and machine learning, these solutions help pharmaceutical and health system clients reach narrowly defined clinician segments with relevant content. This targeted, data-driven approach consistently delivers measurable engagement, encouraging clients to expand usage across multiple brands or service lines. To reinforce retention, Doximity invests in a strong customer success team that works hands-on with clients to fine-tune campaigns, optimize content and provide ongoing analytics. Clients also have access to a self-serve portal for real-time insights. This approach has helped drive upsell opportunities and long-term client relationships. On the enterprise side, Workflow Solutions like Dialer Enterprise and AMiON have seen significant traction. These tools are now embedded into hospital operations, making transitions away from Doximity less likely. Additionally, recent enhancements such as Doximity GPT, an AI-powered, HIPAA-compliant writing assistant, add further value for clients by reducing administrative burden. This month, GoodRx Holdings, Inc. GDRX launched Community Link, enabling independent pharmacies to directly contract with it using cost-plus pricing. This shift enhances pharmacy engagement by improving pricing control and participation in GoodRx's proprietary offering, Integrated Savings Program. This program plays a key role in the company's efforts to improve pharmacy engagement and retention. Also this month, GoodRx introduced a new erectile dysfunction subscription service — offering virtual consults, transparent pricing and home delivery — streamlining consumer access and promoting recurring use through simplified, stigma-free digital care options. Veeva Systems Inc. VEEV continues to strengthen client engagement through its growing Vault CRM Suite, which unifies medical, sales, and service teams around a shared customer view. In its first-quarter fiscal 2026 results, Veeva Systems highlighted momentum in products like Veeva Link and Crossix, which deliver real-time insights and multichannel engagement metrics. By expanding commercial cloud adoption and investing in data-rich, modular platforms, Veeva Systems reinforces customer stickiness, driving higher retention among top-tier life sciences clients. These innovations support more intelligent, coordinated outreach across the customer journey. Shares of Doximity have gained 9.6% year to date against the industry's loss of 0.9%. Image Source: Zacks Investment Research DOCS' forward 12-month P/E of 39.4X is higher than the industry's average of 14.6X, but is lower than its three-year median of 48.9X. It carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for DOCS' fiscal 2026 earnings per share suggests a 3.5% improvement from fiscal 2025. Image Source: Zacks Investment Research Doximity stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Veeva Systems Inc. (VEEV) : Free Stock Analysis Report GoodRx Holdings, Inc. (GDRX) : Free Stock Analysis Report Doximity, Inc. (DOCS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-06-2025
- Business
- Yahoo
2 Growth Stocks to Stash and 1 to Question
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market's punishment can be swift and severe when trajectories fall. Deciphering which businesses can sustain their high growth rates is a challenge for even the most seasoned professionals, which is why we started StockStory. On that note, here are two growth stocks expanding their competitive advantages and one climbing an uphill battle. One-Year Revenue Growth: +25.3% Founded in 2009 by enterprise software veteran Tom Seibel, (NYSE:AI) provides software that makes it easy for organizations to add artificial intelligence technology to their applications. Why Does AI Fall Short? 15.5% annual revenue growth over the last three years was slower than its software peers Extended payback periods on sales investments suggest the company's platform isn't resonating enough to drive efficient sales conversions Historical operating margin losses point to an inefficient cost structure stock price of $25.72 implies a valuation ratio of 7.4x forward price-to-sales. Dive into our free research report to see why there are better opportunities than AI. One-Year Revenue Growth: +32.3% Founded in 2014 and named after the dreaded first day of the work week, (NASDAQ:MNDY) is a software-as-a-service platform that helps organizations plan and track work efficiently. Why Is MNDY a Good Business? ARR trends over the last year show it's maintaining a steady flow of long-term contracts that contribute positively to its revenue predictability Software is difficult to replicate at scale and results in a best-in-class gross margin of 89.5% Strong free cash flow margin of 30.4% enables it to reinvest or return capital consistently is trading at $305 per share, or 12.7x forward price-to-sales. Is now a good time to buy? Find out in our full research report, it's free. One-Year Revenue Growth: +20% Founded in 2010 and named for a combination of 'docs' and 'proximity', Doximity (NYSE: DOCS) is the leading social network for U.S. medical professionals. Why Should DOCS Be on Your Watchlist? Billings have averaged 23.5% growth over the last year, showing it's securing new contracts that could potentially increase in value over time Well-designed software integrates seamlessly with other workflows, enabling swift payback periods on marketing expenses and customer growth at scale DOCS is a free cash flow machine with the flexibility to invest in growth initiatives or return capital to shareholders At $58.44 per share, Doximity trades at 19x forward price-to-sales. Is now the right time to buy? See for yourself in our comprehensive research report, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free.
